Skip to main content
CGTX
NASDAQ Life Sciences

FDA Aligns on Pivotal Phase 3 Design for Cognition Therapeutics' Zervimesine in DLB Psychosis

Tom Rudovsky · Reported by Wiseek News
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$1.74
Mkt Cap
$147.672M
52W Low
$0.25
52W High
$3.83
52W Position info
596% above low
Off High info
55% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

CGTX has more than doubled off its 52-week low of $0.25.

Summary

Cognition Therapeutics has secured FDA alignment on the design of its pivotal Phase 3 trial for zervimesine in Dementia with Lewy Bodies (DLB) psychosis. The FDA also confirmed that DLB psychosis can be an approvable outcome for a New Drug Application. This follows previous positive FDA interactions in May and June regarding the drug's registrational path. This definitive agreement on trial design significantly de-risks the development of their lead candidate. The Phase 3 trial is anticipated to commence in mid-2027.

At the time of this announcement, CGTX was trading at $1.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $147.7M. The 52-week trading range was $0.25 to $3.83. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

CGTX - Latest Insights

CGTX
Nov 05, 2026, 6:15 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.6833
Real-time Price: $0.63005 info
Change: -$0.05325 (-8%) info
Market Cap: $59.918M info
CGTX
Nov 05, 2026, 6:04 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.6833
Real-time Price: $0.63005 info
Change: -$0.05325 (-8%) info
Market Cap: $59.918M info
CGTX
Oct 22, 2026, 6:06 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.800
Real-time Price: $0.63005 info
Change: -$0.16995 (-21%) info
Market Cap: $59.918M info
CGTX
Oct 22, 2026, 6:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.7995
Real-time Price: $0.63005 info
Change: -$0.16945 (-21%) info
Market Cap: $59.918M info
CGTX
Oct 13, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.865
Real-time Price: $0.63005 info
Change: -$0.23495 (-27%) info
Market Cap: $59.918M info